[1] [1] MEYER-SCHWICKERATH G R. The history of photocoagulation[J]. Australian and New Zealand Journal of Ophthalmology, 1989, 17(4): 427-434.

[2] [2] CHHABLANI J, ROH Y J, JOBLING A I,et al. Restorative retinal laser therapy: present state and future directions[J]. Survey of Ophthalmology, 2018, 63(3): 307-328.

[3] [3] KOZAK I, LUTTRULL J K. Modern retinal laser therapy[J]. Saudi Journal of Ophthalmology: Official Journal of the Saudi Ophthalmological Society, 2015, 29(2): 137-146.

[4] [4] SUN Z H, HUANG Y, NIE C C,et al. Efficacy and safety of subthreshold micropulse laser compared with threshold conventional laser in central serous chorioretinopathy[J]. Eye, 2020, 34(9): 1592-1599.

[5] [5] LAVINSKY D, WANG J, HUIE P,et al. Nondamaging retinal laser therapy: rationale and applications to the macula[J]. Investigative Ophthalmology & Visual Science, 2016, 57(6): 2488-2500.

[6] [6] GAWCKI M. Micropulse laser treatment of retinal diseases[J]. Journal of Clinical Medicine, 2019, 8(2): 242.

[7] [7] CHANG D B, LUTTRULL J K. Comparison of subthreshold 577 and 810 nm micropulse laser effects on heat-shock protein activation kinetics: implications for treatment efficacy and safety[J]. Translational Vision Science & Technology, 2020, 9(5): 23.

[8] [8] LUTTRULL J K, DORIN G. Subthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema: a review[J]. Current Diabetes Reviews, 2012, 8(4): 274-284.

[9] [9] FUNG A T, YANG Y, KAM A W. Central serous chorioretinopathy: a review[J]. Clinical and Experimental Ophthalmology, 2023, 51(3): 243-270.

[10] [10] KOBAT S G, YUSUFOGLU E, GUL F C,et al. Plasma dopamine and catecholamine levels in patients with central serous chorioretinopathy[J]. Journal Francais d′Ophtalmologie, 2021, 44(5): 621-625.

[11] [11] SUN J H, TAN J F, WANG Z T,et al. Effect of catecholamine on central serous chorioretinopathy[J]. Current Medical Science, 2003, 23: 313-316.

[12] [12] THOMAS J, ELON H, SUZANNE Y,et al. Central serous chorioretinopathy: towards an evidence-based treatment guideline[J]. Progress in Retinal Research, 2019, 73: 100770.

[13] [13] SEMERARO F, MORESCALCHI F, RUSSO A,et al. Central serous chorioretinopathy: pathogenesis and management[J]. Clinical Ophthalmology, 2019, 13: 2341-2352.

[14] [14] DARUICH A, MATET A, DIRANI A,et al. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis[J]. Progress in Retinal and Eye Research, 2015, 48: 82-118.

[15] [15] IACONO P, POZZO S, VARANO M,et al. Photodynamic therapy with verteporfin for chronic central serous chorioretinopathy: a review of data and efficacy[J]. Pharmaceuticals, 2020, 13(11): 349.

[17] [17] LI X, LONG H, HU Q H. Efficacy of subthreshold micropulse laser for chronic central serous chorioretinopathy: a meta-analysis[J]. Photodiagnosis and Photodynamic Therapy, 2022, 39: 102931.

[18] [18] ZHOU L, LAI K, JIN L,et al. Subthreshold micropulse laser vs. conventional laser for central serous chorioretinopathy: a randomized controlled clinical trial[J]. Frontiers in Medicine, 2021, 8: 682264.

[19] [19] ZHOU L J, HUANG C X, LI Z J,et al. A randomized non-inferiority trial of 577 nm subthreshold micropulse laser versus half-dose photodynamic therapy for acute central serous chorioretinopathy[J]. Photodiagnosis and Photodynamic Therapy, 2024, 45: 103908.

[20] [20] ROCA J A, WU L, FROMOW-GUERRA J,et al. Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group[J]. British Journal of Ophthalmology, 2018, 102(12): 1696-1700.

[21] [21] LEE R, WONG T Y, SABANAYAGAM C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss[J]. Eye and Vision, 2015, 2: 17.

[22] [22] KODJIKIAN L, BELLOCQ D, BANDELLO F,et al. First-line treatment algorithm and guidelines in center-involving diabetic macular edema[J]. European Journal of Ophthalmology, 2019, 29(6): 573-584.

[23] [23] MADJEDI K, PEREIRA A, BALLIOS B G,et al. Switching between anti-VEGF agents in the management of refractory diabetic macular edema: a systematic review[J]. Survey of Ophthalmology, 2022, 67(5): 1364-1372.

[25] [25] ALTINEL M G, ACIKALIN B N, ALIS M G,et al. Comparison of the efficacy and safety of anti-VEGF monotherapy versus anti-VEGF therapy combined with subthreshold micropulse laser therapy for diabetic macular edema[J]. Lasers in Medical Science, 2021, 36(7): 1545-1553.

[26] [26] CITIRIK M. The impact of central foveal thickness on the efficacy of subthreshold micropulse yellow laser photocoagulation in diabetic macular edema[J]. Lasers in Medical Science, 2019, 34(5): 907-912.

[27] [27] AKKAYA S, AIKALIN B, DOAN Y E,et al. Subthreshold micropulse laser versus intravitreal anti-VEGF for diabetic macular edema patients with relatively better visual acuity[J]. International Journal of Ophthalmology, 2020, 13(10): 1606-1611.

[28] [28] FRIZZIERO L, CALCIATI A, TORRESIN T,et al. Diabetic macular edema treated with 577-nm subthreshold micropulse laser: a real-life, long-term study[J]. Journal of Personalized Medicine, 2021, 11(5): 405.

[29] [29] QUERQUES G, QUERQUES L, MARTINELLI D,et al. Pathologic insights from integrated imaging of reticular pseudodrusen in age-related macular degeneration[J]. Retina, 2011, 31(3): 518-526.

[30] [30] BERENBERG T L, METELITSINA T I, MADOW B,et al. The association between drusen extent and foveolar choroidal blood flow in age-related macular degeneration[J]. Retina, 2012, 32(1): 25-31.

[31] [31] LUTTRULL J K, SINCLAIR S H, ELMANN S,et al. Low incidence of choroidal neovascularization following subthreshold diode micropulse laser (SDM) in high-risk AMD[J]. PLoS One, 2018, 13(8): e0202097.

[32] [32] HUANG Z, DENG K Y, DENG Y M,et al. Long-term outcomes of drusenoid pigment epithelium detachment in intermediate AMD treated with 577 nm subthreshold micropulse laser: a preliminary clinical study[J]. International Journal of Ophthalmology, 2022, 15(3): 474-482.

[34] [34] BUYRU Y, AKKAYA S, AKSOY S,et al. Comparison of ranibizumab and subthreshold micropulse laser in treatment of macular edema secondary to branch retinal vein occlusion[J]. European Journal of Ophthalmology, 2018, 28(6): 690-696.

[35] [35] TERASHIMA H, HASEBE H, OKAMOTO F,et al. Combination therapy of intravitreal ranibizumab and subthreshold micropulse photocoagulation for macular edema secondary to branch retinal vein occlusion: 6-month result[J]. Retina, 2019, 39(7): 1377-1384.

[36] [36] LI L, REN Q, SUN Z H,et al. Clinical efficacy of conbercept plus micropulse laser (577 nm) treatment in macular edema secondary to non-ischemic central retinal vein occlusion[J]. Pakistan Journal of Medical Sciences, 2022, 38(5): 1366-1370.

[37] [37] ENG V A, LENG T. Subthreshold laser therapy for macular oedema from branch retinal vein occlusion: focused review[J]. British Journal of Ophthalmology, 2020, 104(9): 1184-1189.

[38] [38] LUTTRULL J K. Improved retinal and visual function following panmacular subthreshold diode micropulse laser for retinitis pigmentosa[J]. Eye, 2018, 32(6): 1099-1110.

[39] [39] KANG Y K, PARK H S. Subthreshold micropulse yellow laser (577 nm) for idiopathic macular telangiectasia type 1 resistant to intravitreal injection[J]. Korean Journal of Ophthalmology, 2020, 34(2): 168-169.

[40] [40] IOVINO C, IODICE C M, PISANI D,et al. Yellow subthreshold micropulse laser in retinal diseases: an in-depth analysis and review of the literature[J]. Ophthalmology and Therapy, 2023, 12(3): 1479-1500.

[41] [41] IOVINO C, DI IORIO V, PAOLERCIO L,et al. Navigated 577-nm subthreshold micropulse retinal laser treatment for peripapillary pachychoroid syndrome[J]. American Journal of Ophthalmology Case Reports, 2022, 28: 101757.